DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chauret, N.
Right arrow Articles by Crespi, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chauret, N.
Right arrow Articles by Crespi, C. L.

Vol. 29, Issue 9, 1196-1200, September 2001

The Use of 3-[2-(N,N-Diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a Specific CYP2D6 Probe in Human Liver Microsomes

Nathalie Chauret, Barry Dobbs, Rebecca L. Lackman, Kevin Bateman, Deborah A. Nicoll-Griffith, David M. Stresser, Joseph M. Ackermann, Stephanie D. Turner, Vaughn P. Miller, and Charles L. Crespi

Merck Frosst Canada, Kirkland, Québec, Canada (N.C., B.D., R.L.L., K.B., D.A.N.-G.); and GENTEST Corporation, BD Biosciences, Woburn, Massachussets (D.M.S., J.M.A., S.D.T., V.P.M., C.L.C.)

Recently, a novel nonfluorescent probe 3-[2-(N,N-diethyl-N-methylammonium)-ethyl]-7-methoxy-4-methylcoumarin (AMMC), which produces a fluorescent metabolite AMHC (3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-hydroxy-4-methylcoumarin) was used with microsomes containing recombinant enzymes (rCYP) to monitor CYP2D6 inhibition in a microtiter plate assay. This article describes the studies that were performed in human liver microsomes (HLM) to establish the selectivity of AMMC toward CYP2D6. Metabolism studies in HLM showed that AMMC was converted to one metabolite identified by mass spectrometry as AMHC. Kinetic studies indicated an apparent Km of 3 µM with a Vmax of 20 pmol/min · mg of protein for the O-demethylation reaction. The O-demethylation of AMMC in HLM was inhibited significantly in the presence of a CYP2D6 inhibitory antibody. Using a panel of various HLM preparations (n = 12), a good correlation (r2 = 0.95) was obtained between AMMC O-demethylation and bufuralol metabolism, a known CYP2D6 substrate, but not with probes for the other major xenobiotic metabolizing CYPs. Finally, only rCYP2D6 showed detectable metabolism in experiments conducted with rCYPs using AMMC at a concentration of 1.5 µM (near Km). However, at a concentration of 25 µM AMMC, rCYP1A also contributed significantly to the formation of AMHC. Knowing the experimental conditions under which AMMC was selective for CYP2D6, a microtiter assay was developed to study the inhibition of various compounds in HLM using the fluorescence of AMHC as an indication of CYP2D6 activity. The inhibition potential of various chemicals was found to be comparable to those determined using the standard CYP2D6 probe, bufuralol, which requires high-performance liquid chromatography separation for the analysis of its CYP2D6-mediated 1'-hydoxylated metabolite.


Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
S. Sudsakorn, J. Skell, D. A. Williams, T. J. O'Shea, and H. Liu
Evaluation of 3-O-Methylfluorescein as a Selective Fluorometric Substrate for CYP2C19 in Human Liver Microsomes
Drug Metab. Dispos., June 1, 2007; 35(6): 841 - 847.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
M. T. Donato, N. Jimenez, J. V. Castell, and M. J. Gomez-Lechon
FLUORESCENCE-BASED ASSAYS FOR SCREENING NINE CYTOCHROME P450 (P450) ACTIVITIES IN INTACT CELLS EXPRESSING INDIVIDUAL HUMAN P450 ENZYMES
Drug Metab. Dispos., July 1, 2004; 32(7): 699 - 706.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
D. M. Stresser, S. D. Turner, A. P. Blanchard, V. P. Miller, and C. L. Crespi
Cytochrome P450 Fluorometric Substrates: Identification of Isoform-Selective Probes for Rat CYP2D2 and Human CYP3A4.
Drug Metab. Dispos., July 1, 2002; 30(7): 845 - 852.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
K. A. Marcucci, R. E. Pearce, C. Crespi, D. T. Steimel, J. S. Leeder, and A. Gaedigk
Characterization of Cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 Activities toward Model CYP2D6 Substrates Dextromethorphan, Bufuralol, and Debrisoquine
Drug Metab. Dispos., May 1, 2002; 30(5): 595 - 601.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.